About Profound Medical Corp.
https://www.profoundmedical.comProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
CEO
Arun Swarup Menawat
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-10-16 | Reverse | 1:10 |
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FIL LTD
Shares:1.89M
Value:$14.36M
GAGNON SECURITIES LLC
Shares:1.73M
Value:$13.21M
LETKO, BROSSEAU & ASSOCIATES INC
Shares:986.25K
Value:$7.52M
Summary
Showing Top 3 of 52
About Profound Medical Corp.
https://www.profoundmedical.comProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.23M ▲ | $12.7M ▼ | $-7.89M ▲ | -150.82% ▲ | $0.26 ▲ | $-7.62M ▲ |
| Q2-2025 | $2.21M ▼ | $15.42M ▲ | $-15.7M ▼ | -709.86% ▼ | $-0.52 ▼ | $-13.66M ▼ |
| Q1-2025 | $2.62M ▼ | $13.02M ▼ | $-10.72M ▼ | -409.16% ▼ | $-0.36 ▼ | $-11M ▲ |
| Q4-2024 | $5.33M ▲ | $86.1M ▲ | $-7.67M ▲ | -143.97% ▲ | $-0.19 ▲ | $-12.06M ▼ |
| Q3-2024 | $3.83M | $-9.71M | $-12.66M | -330.65% | $-0.38 | $-11.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $24.83M ▼ | $42.3M ▼ | $10.16M ▼ | $32.14M ▼ |
| Q2-2025 | $35.2M ▼ | $49.67M ▼ | $10.41M ▲ | $39.26M ▼ |
| Q1-2025 | $46.43M ▼ | $60.86M ▼ | $10.07M ▲ | $50.79M ▼ |
| Q4-2024 | $54.91M ▲ | $70.23M ▲ | $9.81M ▼ | $60.42M ▲ |
| Q3-2024 | $27.12M | $42.23M | $11.17M | $31.06M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.89M ▲ | $-9.48M ▲ | $0 | $2.27K ▼ | $-10.47M ▲ | $-9.48M ▲ |
| Q2-2025 | $-15.95M ▼ | $-14.07M ▼ | $0 | $5.47K ▲ | $-11.16M ▼ | $-14.07M ▼ |
| Q1-2025 | $-10.72M ▼ | $-8.28M ▼ | $0 | $-290K ▼ | $-8.48M ▼ | $-8.28M ▼ |
| Q4-2024 | $-5.33M ▲ | $-5.64M ▲ | $0 | $35.65M ▲ | $27.79M ▲ | $-5.64M ▲ |
| Q3-2024 | $-9.37M | $-6.83M | $0 | $-592K | $-6.96M | $-6.83M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Capital Equipment | $0 ▲ | $0 ▲ | $0 ▲ |
 Recurring NonCapital | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|
 CALIFORNIA | $0 ▲ | $0 ▲ | $0 ▲ |
 CANADA | $0 ▲ | $0 ▲ | $0 ▲ |
 DELAWARE | $0 ▲ | $0 ▲ | $0 ▲ |
 GERMANY | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $10.00M ▲ | $0 ▼ |
CEO
Arun Swarup Menawat
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-10-16 | Reverse | 1:10 |
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FIL LTD
Shares:1.89M
Value:$14.36M
GAGNON SECURITIES LLC
Shares:1.73M
Value:$13.21M
LETKO, BROSSEAU & ASSOCIATES INC
Shares:986.25K
Value:$7.52M
Summary
Showing Top 3 of 52